ESC 365 - Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy

Open Access

Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy

Session: ePosters in chronic heart failure - pharmacotherapy (4)

Topic: Pharmacotherapy

Speaker: Professor M. Fontana (London, GB)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

68 presentations

39 followers

6 more presentations in this session

The spot urinary sodium determination in short-term decongestion therapy

Speaker: Doctor A. Georgakopoulos (Veria, GR)

Patient-dependent factors limiting guideline-directed medical therapy in patients with heart failure with reduced left ventricular ejection fraction undergoing scheduled hospitalization

Speaker: Doctor A. Galas (Warsaw, PL)

Implementation of recommendations regarding pharmacotherapy optimization in patients with heart failure undergoing scheduled hospitalization - the HEROES study.

Speaker: Doctor A. Galas (Warsaw, PL)

Reasons for underutilization of medical therapy for heart failure with reduced ejection fraction

Speaker: Doctor K. Berge (Nordbyhagen, NO)

Efficiency of guideline-directed medical therapy in patients with acute decompensated heart failure and subclinical congestion at discharge.

Speaker: Doctor N. Khutsishvili (Tbilisi, GE)

Access the full session

ePosters in chronic heart failure - pharmacotherapy (4)

Speakers: Professor M. Fontana, Doctor A. Georgakopoulos, Doctor A. Galas, Doctor A. Galas, Doctor K. Berge...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources